In Vivo Recognition of Human Vascular Endothelial Growth Factor by Molecularly Imprinted Polymers by Cecchini, Alessandra et al.
                                                              
University of Dundee
In Vivo Recognition of Human Vascular Endothelial Growth Factor by Molecularly
Imprinted Polymers
Cecchini, Alessandra; Raffa, Vittoria; Canfarotta, Francesco; Signore, Giovanni; Piletsky,









Link to publication in Discovery Research Portal
Citation for published version (APA):
Cecchini, A., Raffa, V., Canfarotta, F., Signore, G., Piletsky, S., MacDonald, M., & Cuschieri, A. (2017). In Vivo
Recognition of Human Vascular Endothelial Growth Factor by Molecularly Imprinted Polymers. Nano Letters,
17(4), 2307-2312. https://doi.org/10.1021/acs.nanolett.6b05052
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
1 
In Vivo Recognition of Human Vascular Endothelial 
Growth Factor by Molecularly Imprinted Polymers 
Alessandra Cecchini@, Vittoria Raffa*@#, Francesco Canfarotta$, Giovanni Signore%+, Sergey 
Piletsky^, Michael P. MacDonald& and Alfred Cuschieri*@
@IMSaT, University of Dundee, 1 Wurzburg Loan, Dundee DD2 1FD, UK 
#Department of Cellular and Developmental Biology, Università di Pisa, S.S. 12 Abetone e 
Brennero 4, 56127 Pisa, Italy 
$MIP Diagnostics Ltd, University Road, Leicester LE1 7RH, UK 
%Center for Nanotechnology Innovation @NEST, Istituto Italiano di Tecnologia, Piazza San 
Silvestro 12, 56127 Pisa, Italy 
+NEST, Scuola Normale Superiore, and Istituto Nanoscienze-CNR, Piazza San Silvestro 12, 
56127 Pisa, Italy 
^Department of Chemistry, University of Leicester, University Road, Leicester LE1 7RH, UK 
&School of Science and Engineering, University of Dundee, Nethergate, DD1 4HN, UK 
IMSaT, University of Dundee, 1 Wurzburg Loan, Dundee DD2 1FD, UK 
ABSTRACT One of the mechanisms responsible for cancer-induced increased blood supply in 
malignant neoplasms is the overexpression of vascular endothelial growth factor (VEGF). 
Several antibodies for VEGF targeting have been produced for both imaging and therapy. 
This document is the unedited author's version of a Submitted Work that was subsequently accepted 
for publication in Nano Letters, copyright © American Chemical Society after peer review. To access 
the final edited and published work, see http://pubs.acs.org/doi/abs/10.1021/acs.nanolett.6b05052.
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Molecularly imprinted polymer nanoparticles, nanoMIPs, however, offer significant advantages 
over antibodies, in particular in relations to improved stability, speed of design, cost and control 
over functionalization. In the present study, the successful production of nanoMIPs against 
human VEGF is reported for the first time. NanoMIPs were coupled with quantum dots (QDs) 
for cancer imaging. The composite nanoparticles exhibited specific homing towards human 
melanoma cell xenografts, overexpressing hVEGF, in zebrafish embryos. No evidence of this 
accumulation was observed in control organisms. These results indicate that nanoMIPs are 
promising materials which can be considered for advancing molecular oncological research, in 
particular when antibodies are less desirable due to their immunogenicity or long production 
time. 
KEYWORDS molecularly imprinted polymers, composite nanoparticles, zebrafish embryos, 
cancer imaging, human vascular endothelial growth factor  
Angiogenesis is a physiological process concerned with the formation of new blood vessels, 
essential for sustained viability and growth of malignant solid tumors1. This process ensures an 
adequate blood supply required by various intracellular machineries within cancer cells, e.g. 
systems driving RNA and protein synthesis, intracellular transport, abnormal tumor-specific 
metabolic pathways, organelles integrity preservation, etc. Many of the mechanisms involved in 
these processes remain unresolved, but should become amenable to investigation by molecular-
oncological studies carried out by exploiting nanoMIPs. In particular, nanoMIPs, which possess 
antibody-like properties, are able to cross the cell membrane. Hence, they bear significant 
potential in accelerating the development of drugs which targets cellular machineries involved in 
growth and spread of tumor cells, in sharp contrast to conventional chemotherapy agents, which 
aim to target tumor DNA. Anti-cancer machinery drugs based on this alternative approach to 
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anti-cancer therapy have been reviewed recently2. Amongst the effectors involved in 
angiogenesis, vascular endothelial growth factor (VEGF) stands out as being the most 
intensively investigated over the years for its crucial role in this process, both in health and 
disease3,4. Indeed, VEGF is overexpressed in many invasive cancers (breast, colorectal, 
gastrointestinal, etc.)5.Through its autocrine secretory activity, it stimulates proliferation of 
tumor cells together with proliferation and differentiation of endothelial cells3. Targeting of 
VEGF by monoclonal antibodies (mAbs) has been proposed for imaging and detection of the 
tumor mass6,7,8. Additionally, this strategy has been widely exploited for the treatment of several 
cancers, usually in combination with cytotoxic agents, and it is showing promising results in 
clinical phase I and phase II with certain cancers5. Examples of anti-VEGF antibodies in clinical 
use or in clinical trial are 2C3, r84, VEGF-trap and particularly Bevacizumab9. However, the 
research in angiogenesis continues with hundreds of groups worldwide developing new ligands, 
such as aptamers, and new anti-VEGF treatment procedures10. There are numbers of issues that 
remain unresolved in relations to the use of antibodies in research, diagnostics and clinical 
practice. For instance, production of mAbs is a long, complex and expensive process. Poor cell 
membrane permeability and possible immunogenic reactions often limit their therapeutic 
application11. Even humanized mAbs can elicit immune reactions12,13,14 and many have serious, 
sometimes fatal consequences, e.g., severe neutropenia15. Furthermore, functionalization of 
mAbs with fluorescent reporters or magnetic particles often alter their binding properties. In 
contrast, the use of molecularly imprinted polymer nanoparticles (nanoMIPs) as molecular active 
targeting tools has the potential to avert these complications. Molecular imprinting has been 
extensively exploited for various applications from analytical chemistry to nanomedicine16. 
Recently, a novel approach for the production of nanoMIPs, i.e. solid-phase molecular 
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imprinting, has been developed  leading to the production of MIPs with antibody-like affinity for 
small drugs, peptides and entire proteins17. The increasing interest in employing nanoMIPs for 
biological applications in preference to antibodies is due to their remarkable properties, e.g., high 
stability and long shelf life, short development time and low production cost, high affinity and 
specificity as well as ease of functionalization. NanoMIPs have been utilized as innovative 
recognition ligands and active targeting tools for the imaging of key molecules, either in vitro or 
in vivo18,19,20,21,22,23. For example, nanoMIPs have been imprinted against molecules overexpressed 
on the cell surface24,25. In this article, we demonstrate for the first time the successful imprinting 
of the secreted effector of angiogenesis, human VEGF (hVEGF), which has been proven to play 
a pivotal role in many invasive cancers and types of leukemia. NanoMIPs targeting hVEGF were 
produced by solid-phase synthesis and coupled to quantum dots (QDs) to enable fluorescent 
imaging in vivo. Their ability to specifically target hVEGF and homing towards the tumor mass 
was confirmed in xenotransplantation of human malignant melanoma cells in zebrafish 
embryos26. These new highly fluorescent nanoMIPs can be used for the study of angiogenesis as 
well as potential imaging tools in cancer diagnostics.  
 
For this study, a synthetic nine-aminoacid surface epitope of hVEGF (amino acids 83–91: 
IKPHQGQHI) (Figure 1c) was selected as template for the solid-phase synthesis of nanoMIPs 
against hVEGF. The epitope choice was dictated by specific criteria including: (i) compatibility 
with the molecular imprinting technology (i.e. short epitope); (ii) possibility to add a terminal 
cysteine for the immobilization onto the solid phase; (iii) accessibility (i.e. surface epitope) 
(Figure 1a – b); (iv) relevance of the sequence of the epitope (i.e. specific of hVEGF and in the 
receptor recognition region of hVEGF). The epitope was selected after literature research27, 
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modified with a terminal cysteine (final sequence: IKPHQGQHI–C), and immobilized onto 
micrometric glass beads for the subsequent solid-phase synthesis of anti-hVEGF nanoMIPs.  
  
Figure 1. The structure of human vascular endothelial growth factor (hVEGF) and the selected 
epitope, in complex with VEGF receptor FLT-1. (a) Virtual image of hVEGF associated to its 
receptor FLT-1 and the position of the chosen epitope for the solid-phase synthesis. (b) Rotated 
virtual image of hVEGF associated to its receptor FLT-1; it is possible to better observe from a 
different angle the position of the epitope in the whole sequence in the recognition site of the 
receptor. (c) The selected nine-aminoacid epitope of hVEGF (IKPHQGQHI) isolated from the 
whole sequence. 
 
We elected to couple the recognition property of nanoMIPs with high brightness and high-
photostability 710 nm emitting CdTe QDs, as NIR emission can be exploited to perform in vivo 
imaging with high spatial resolution, deep tissue penetration and low auto-fluorescence. We 
adopted two different approaches to generate the final fluorescent hybrid nanoprobe – QD-MIPs. 
One approach was based on the incorporation of commercial carboxyl-functionalized QDs into 
the MIP matrix (i.e. within the nanoMIPs) during the polymerization process (Figure 2a) – QD-
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MIPs (embedded). This was achieved by previous functionalization of the QDs with the 
functional monomer N-(3-aminopropyl) methacrylamide. Although QDs were successfully 
embedded within MIP matrix (Figure 2c), QD-MIPs obtained by this approach did not exhibit 
any fluorescence signal, probably because of quenching events following the polymerization 
process. The other strategy aimed to covalently couple the QDs onto the MIP surface after the 
polymerization process (Figure 2a) – QD-MIPs (attached). TEM images of QD-MIPs (attached) 
revealed the successful attachment of QDs onto the surface of pre-synthesized MIPs (Figure 2d). 
QD-MIPs showed an emission peak at 730 nm; shifted 20 nm towards infrared when compared 
to free QDs (Figure 2e). This shift was previously encountered for QDs functionalized with 
monomer N-(3-aminopropyl) methacrylamide, exploited in the first approach. Though the 
precise mechanism for this shift in the emission peak is not known, it is to be expected due to the 
close coupling of the QDs to the monomers28. Control polymers imprinted against non-target 
vancomycin were also coupled to QDs following the second approach. Similarly, the obtained 
control nanoprobes – QD-nips – were observed to bear fluorescence after the functionalization 
(Figure S2a). QD-MIPs were characterized in terms of size, affinity and specificity for the 
template, and their ability to bind the entire protein hVEGF. Dynamic light scattering 
measurements confirmed the production of QD-MIPs with 171.4 ± 36.3 nm hydrodynamic 
diameter (Figure 2f), whereas QD-nips show diameter of 140.2 ± 16 nm (Figure S2b)29. 
Additionally, we performed nanoparticle tracking analysis (NTA) on hybrid nanoprobes and 
non-functionalized MIPs. Particularly, QD-MIPs showed diameter of 140.0 ± 6.8 nm, whereas 
MIPs 120.6 ± 10.5 nm diameter (Figure S1, Table S3). As expected, NTA measurement 
provided slightly smaller values than the ones detected with DLS, since DLS measures the light 
scattered from each nanoparticle in the sample as a whole, giving an average measurement. Z 
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potential measurements showed a shift of the surface charge of QD-MIPs (attached) (-11.9 ± 0.8 
mV) from the value of non-functionalized MIPs (-27.5 ± 4.8 mV) to the less negative value 
obtained for free QD (-3.76 ± 2.0 mV), confirming the presence of QDs onto the surface of 
nanoMIPs (Figure S1, Table S3). Conversely, QD-MIPs (embedded) were found to present 
similar surface charge to non-functionalized MIPs (Table S1).    
 
Figure 2. Scheme of the polymerization approach and the strategy to produce the QD-MIP 
nanoprobes, together with TEM images, fluorescence and size measurements. (a) Cartoon of the 
two strategies exploited to produce QD-MIPs, based on solid-phase synthesis: (i) embedding the 
QDs in the MIP matrix during its polymerization; (ii) attaching the QDs onto the nanoMIPs after 
the polymerization process. TEM images of (b) QDs which appear as electron-dense spots 2-4 
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nm in size (inset), (c) MIP with incorporated electron-dense QDs in the matrix (arrows) – QD-
MIP (embedded), (d) MIP exhibiting a surface decorated with electron-dense QDs (arrows) – 
QD-MIP (attached). (e) Fluorescence profile of QD-MIPs with QDs embedded into the MIPs 
during the polymerization - QD-MIPs (embedded) -, QD-MIPs with QDs attached via EDC/NHS 
onto the nanoMIPs surface after the polymerization step – QD-MIPs (attached) -, and free QDs 
(Graph obtained with Qti-plot). (f) Dynamic light scattering measurements of fluorescent QD-
MIPs polymerized in PBS against the epitope of hVEGF with hydrodynamic diameter 171.4 ± 
36.3 nm (n=6). 
 
The affinity of QD-MIPs imprinted against the epitope of hVEGF was assessed using a surface 
plasmon resonance (SPR) instrument (Biacore 3000). In particular, QD-MIPs were covalently 
immobilized on the sensor surface and increasing concentrations of the epitope were injected. 
QD-MIPs showed an excellent affinity for the epitope, with KD in the low nanomolar range (1.56 
± 0.20 nM) and low Chi2 values (Table S1, Figure 3a). Similarly, QD-MIPs were also able to 
bind the whole hVEGF protein. The graph in Figure 3b shows the binding and dissociation 
curves after the injection of 40 nM recombinant hVEGF. Furthermore, the binding is highly 
specific, as exemplified by SPR measurements which demonstrated absence of binding of QD-
MIPs to a non-target molecule. We decided to focus our attention on a molecule similar in terms 
of isoelectric point to our whole-sequence target hVEGF (8.5) and cysteine-epitope (8.14); for 
which we chose the antibiotic vancomycin (8.14). This molecule was not recognized by QD-
MIPs even at concentrations up to 1 μM (three orders of magnitude higher than the ones used for 




Figure 3. Surface plasmon resonance measurements obtained with a Biacore 3000 instrument 
(GE Healthcare). (a) Binding curves of QD-MIPs imprinted against the epitope of hVEGF and 
tested for the epitope. For the calculation of the affinity for the epitope, 6 different 
concentrations of the epitope (ranging from 97 pM to 100 nM) were injected on the QD-MIP 
functionalized gold chip exploited for the analysis. (b) Binding assessment of the QD-MIPs for 
the whole protein hVEGF (concentration injected 40 nM). (c) Binding curves of QD-MIPs 
imprinted against the epitope of hVEGF after injection of 6 different concentrations of the non-
target vancomycin (97 pM – 100 nM), for assessing the specificity of QD-MIPs for the epitope. 
(d) Binding curves of QD-MIPs after injection of 6 different concentrations of the non-target 
vancomycin (10 nM – 1 µM), for assessing the specificity of QD-MIPs for the epitope. 




SPR measurements were also performed using an epitope of the epidermal growth factor 
receptor (EGFR) as control protein. Interestingly, EGFR is endogenously produced in zebrafish30 
and it is known to be involved in angiogenesis, therefore it could be one of the proteins exposed 
to QD-MIPs in xenotransplanted zebrafish embryos. Concentrations of EGFR epitope ranging 
from 97 pM to 100 nM (as per hVEGF epitope and vancomycin) were injected (Figure S). The 
goodness of the fit of data obtained from Biacore measurements was poor and therefore it did not 
allow calculating any KD, which resulted in the confirmation of specificity of our hybrid 
nanoprobes for hVEGF template.  
SPR measurements allowed us to conclude that QD-MIPs imprinted against hVEGF had high 
affinity and specificity for the epitope and were able to bind the whole hVEGF. 
The next step in our experiments was to assess the ability of QD-MIPs to localize in vivo, namely 
in tumor xenografts in zebrafish embryos. Specifically, a melanoma cell line known to 
overexpress hVEGF was exploited to create the in vivo model.  Zebrafish embryos were selected 
as animal model for this study for several reasons: (i) ‘casper’ transgenic fish are transparent; (ii) 
their maintenance and manipulation are straightforward; (iii) they develop quickly compared to 
mice; (iv) zebrafish are a widely used model in studies of human tumors; (vi) they can be used at 
unlicensed development stages, within the temporal window between the fecundation and 96 
hours post fertilization (hpf) (rejection-free xenografts)31. Two tumor models were obtained by 
injecting two human melanoma cell lines in the yolk of 48 hpf zebrafish embryos: (i) WM-266, 
overexpressing hVEGF (called hVEGF (+) model hereafter) and (ii) A-375, with low expression 
of hVEGF (called hVEGF (-) model hereafter)32,33. Targeted and non-targeted nanoMIPs (i.e., 
nanoMIPs imprinted against vancomycin, QD-nips hereafter) were administered 24 hours after 
the injection of the tumor cells. Specifically, QD-MIPs were injected in both the hVEGF (-) and 
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the hVEGF (+) models, whereas QD-nips were administered only to the hVEGF (+) model 
(Figure 4a). Initially, we performed a study on the toxicity of these hybrid nanoprobes in 
zebrafish embryos. The effect of QD-MIP injection in the animals was evaluated. Any toxic 
effects should result in reduced viability and/or alterations of normal development. The most 
common phenotype mutations caused by nanoparticles in zebrafish embryos include intestinal 
defects, tail or spinal cord flexure, fin-fold abnormalities, yolk sac edema, absence of tail, 
twisted notochord, pericardial edema, degeneration of body parts, jaw defects, head skeleton 
defects, neurological damage and anencephaly31. QD-MIPs were injected in the yolk of 48 hpf 
zebrafish embryos. Twenty-four hours post-injection, the embryos were imaged and dead or 
aberrant phenotypes were recorded. Data analysis showed no statistically significant difference 
between groups (n=40, p>0.5, Chi2 test) (Figure S). We can conclude that, for the purpose of this 
study, QD-MIPs induce negligible toxic effects. Prior to start experiments of QD-MIP homing 
towards the tumor, we sought to find the most appropriate incubation time to allow efficient 
diffusion without incurring loss of the fluorescent reporter. To this end, 48 hpf zebrafish embryos 
were injected with QD-MIPs and then sacrificed at different incubation times: time 0, 2.5 hours 
and overnight (20 hours). Thereafter, embryos were digested and their cadmium content, a 
marker of QD-MIPs concentration, was analyzed by inductively coupled plasma mass 
spectrometry. The results showed significant decrease in cadmium concentration down to 57% in 
the 2.5-hour incubation sample, compared to time 0 incubation. Cadmium signal was even lower 
in overnight incubation sample (36%) compared to time 0 (Table S2). Based on these findings, 
we incubated the nanoprobes for 7 hours in either hVEGF (+) or hVEGF (-) zebrafish models. 
This time was selected as a reasonable compromise between the long interval necessary to allow 
diffusion of nanoprobes in the yolk of zebrafish embryos and fluorescence signal loss. Confocal 
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microscopy was used to detect the in vivo distribution of injected nanoprobes and to compare it 
with the tumor mass localization. Considering the nature of hVEGF as secreted effector of 
angiogenesis, we did not expect to observe co-localization of the QD-MIPs with WM-266 cells, 
but mostly homing of the nanoprobes towards cancer cells. Notably, Figure 4b shows that QD-
MIPs were actually able to home towards the cells in hVEGF (+) model and specifically localize 
in close proximity to the tumor mass. In contrast, in both controls, QD-MIPs in hVEGF (-) 
model and QD-nips in hVEGF (+) model, nanoprobes did not localize with the tumor mass 
(Figure 4b). Importantly, data analysis highlighted a statistically significant difference in the 
means of the nanoprobe-cell distances between the QD-MIPs injected in hVEGF (+) embryos 





Figure 4. Overview of the in vivo experiments carried out exploiting zebrafish embryos to 
investigate the ability of QD-MIPs to localize with cancer cells overexpressing hVEGF. (a) 
Scheme of the in vivo experiments: (i) QD-MIPs imprinted against hVEGF injected in hVEGF 
(+) model, (ii) QD-MIPs injected in hVEGF (-) model, (iii) QD-nips imprinted against 
vancomycin injected in hVEGF (+) model. (b) Panel of the bright field and fluorescence images 
of human melanoma cells (WM-266 hVEGF (+) model and A-375 hVEGF (-) model) (green) 
and the fluorescent nanoprobes (red), acquired with a confocal microscope Leica SP2 (scale bar 
100µm), and the overlay of the two signal. (c) Statistical analysis of the mean of distances 
nanoprobe-cell (µm) in the three different scenarios: QD-MIPs injected in hVEGF (+) model, 
QD-nips injected in WM-266 hVEGF (+) model, and QD-MIPs injected in hVEGF (-) model. 




In the present study, we demonstrate that QD-MIP hybrid nanoprobes, emitting in the near-
infrared and imprinted against the surface epitope of hVEGF, recognize and selectively bind to 
the entire protein in vitro, and home towards the tumor mass overexpressing hVEGF in in vivo 
tumor xenograft experiments. Here, we demonstrate for the first time that a secreted factor has 
been successfully targeted using MIP-based composite nanoparticles. Hence, these findings 
indicate the significant potential of nanoMIPs, paving the way for additional studies to target 
other secreted factors in several human disorders. We also conclude that nanoMIPs may 
represent a viable alternative to conventional active targeting ligands such as monoclonal 
antibodies. The main advantages of MIPs as compared with mAbs are related to their rapidity of 
development (3 days for synthesis and functionalization of nanoMIPs), long shelf-life, easy 
functionalization, good biocompatibility, solubility and ability to cross the cell membrane and 
lack of immunogenic response34. The versatility of the solid-phase synthesis approach should 
permit the coupling of nanoMIPs with multiple fluorescent reporters or cargos. Magnetic 
nanoparticles would have to be considered as contrast agents for magnetic resonance imaging for 
clinical translation of this strategy, or Cd-free QDs, especially in view of the advances in their 
composition and increased biocompatibility in recent years. By virtue of their ease of 
functionalization, nanoMIPs could be conjugated to various drugs for non-invasive detection of 
early subclinical cancer and simultaneous drug therapy. Additionally, since the epitope exploited 
as a template for solid-phase polymerization is strongly involved in the recognition of the 
hVEGF receptor, these nanoprobes may exhibit antagonist properties as anti-VEGF therapeutic 
agents, and therefore its angiogenetic cascade. Experiments are currently being planned in our 
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